Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
Candoni, Anna
•
Papayannidis, Cristina
•
Martinelli, Giovanni
altro
Fanin, Renato
2018